HIV

Pharmacists can help eliminate certain barriers to condom use by understanding the range of products available.

Study highlights the importance of understanding, addressing, and bridging gaps in achieving viral suppression.

The study's findings show that patients with HIV will forgo short travel distances and wait times in order to access a health care provider with a positive attitude.

A new HIV therapy demonstrated its efficacy in reducing the virus and boosting immunity in drug-resistant patients, according to a recent published study.

Phase 3 study results showed that the new HIV therapy ibalizumab reduced viral replication and increased immunity in drug-resistant patients.

According to a recent study, older adults and Hispanics are less likely to receive HIV testing, indicating an urgent need for improved interventions.

Interventions must address HIV testing and beliefs among both patients and providers in order to reach underserved populations.

Patients with HIV have a high likelihood of developing depression related to their diagnosis, according to a recent study., and many of them do not seek medical care.

New research demonstrates continued virologic control in patients with HIV-1 following a switch to Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg [D/C/F/TAF]) regardless of prior treatment regimen

Clinical data demonstrate continued virologic response rates in patients with HIV switching to Symtuza from boosted protease inhibitor-based regimens.

While the prevalence of neurological disabilities among children with HIV has drastically decreased since the emergence of antiretroviral therapy, the prevalence remains higher in this patient population

A look at last week's top stories in the world of pharmacy.

HIV-associated cardiovascular disease is on the rise among individuals living with the virus, particularly in regions with limited resources.

Top news of the day from across the health care landscape.

Study evaluates doravirine once daily compared with ritonavir-boosted darunavir, each taken in combination with other antiretroviral agents.

Use of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg) for HIV prevention was associated with a significant decline in new diagnoses across the United States.

As people living with HIV now have a normal life expectancy, the burden of comorbidities is on the rise, and more than half of deaths in the patient population are attributable to the these comorbidities.

Nationwide analysis of Truvada for pre-exposure prophylaxis use finds uptake associated with significant decrease in new HIV infections.

A new study suggests that pre-exposure prophylaxis (PrEP) could also serve as a gateway to primary care services.

Top news of the day from across the health care landscape.

The HIV pandemic will likely continue to be a global challenge for the foreseeable future.

Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) is the first and only complete darunavir-based single tablet regimen (STR) for the treatment of HIV-1 in treatment-naïve and certain virologically suppressed adults.

The approval is based on data from 2, phase 3 studies, AMBER and EMERALD, which evaluated the safety and efficacy of Symtuza compared with a control regimen in adults with no prior antiretroviral (ARV) history and in virologically suppressed adults.

Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) offers a new treatment option to adults living with HIV.

Health care providers who offer HIV tests encourage patients to integrate preventive screenings into their health care routines.

The CDC and FDA are currently investigating a multistate outbreak of Cyclospora infections (cyclosporiasis) linked to McDonald’s salads.

Mobile health interventions have the potential to help people living with HIV improve engagement in care, promote medication adherence, and in turn, improve patient outcomes.

Point-of-care testing can help patients determine whether or not they need to see a prescriber for an antibiotic or for other types of treatment, and it can address the growing primary care provider shortage.

An experimental HIV-1 vaccine regimen was well-tolerated and produced immune responses against HIV in humans and rhesus monkeys.